| アブストラクト | INTRODUCTION: Limited data are available regarding the prevalence of thrombotic/cardiovascular disease and treatment patterns for patients with coronavirus disease 2019 (COVID-19) in Japan. In this study we describe patients hospitalized for COVID-19 in Japan. METHODS: This retrospective database study analyzed the Japan Medical Data Vision database (416 acute care hospitals) for patients hospitalized for COVID-19 during the identification period from 1 January 1 to 30 September 2020. RESULTS: Among 9282 eligible patients, 832 (9%) had developed thrombotic disease including myocardial infarction, ischemic stroke, deep vein thromboembolism and pulmonary embolism. Intriguingly, 171(1.8%) had two thrombotic events and 25 (0.3%) had three or four thrombotic events at the same time. The data also showed that arterial thrombotic events accounted for 77% of total thrombotic events. Anticoagulant and/or antiplatelet medication was provided to 3312 patients. Even with antithrombotic medication, 21.2% of patients suffered from thrombotic diseases. CONCLUSIONS: Patients with COVID-19 could experience thrombotic complications in every blood vessel. Further optimization of medication is crucial for preventing thrombotic complications and improving prognosis. |
|---|
| ジャーナル名 | Cardiology and therapy |
|---|
| Pubmed追加日 | 2022/4/16 |
|---|
| 投稿者 | Terasaka, Naoki; Matsuo, Yukako; Kataoka, Hirohide; Miyata, Yasuhiko; Anazawa, Yoshio |
|---|
| 組織名 | Medical Department, Bristol Myers Squibb K.K., Tokyo, Japan.;Naoki.Terasaka@bms.com. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/35426621/ |
|---|
